Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is phase 1 multi-centre dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma.

Objectives

  • To establish maximum tolerated dose of AZD8931 in combination with Xelox chemotherapy and define the safety of the combination and safety of post-operative AZD8931 maintenance therapy.
  • Also to assess early efficacy data as determined by progression free survival (PFS) at 6 months and complete resection rate (R0). Pharmacodynamic biomarkers including blood, tissue and imaging will also be investigated to help select a patient population for further studies.

Our team

  • Sarah Pearson

    OCTO Trial Management Director